A Phase 3 interventional study of TAK-438 and TAK-438 in Erosive Esophagitis, sponsored by Takeda. Completed at 37 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-08-23.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing vonoprazan in Esophagitis — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Esophagitis.
Among the 10 studies testing vonoprazan in Esophagitis, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 7 in phase 3, and was the 3rd registered.
123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.
Browse Esophagitis studies →1 of the 10 studies testing vonoprazan in Esophagitis is open now, in 1 country. Recruiting first, the newest first:
Indonesia University · Sites in Indonesia
Ages 18+
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2011.
This study's enrollment of 607 is above the median of 96 across 99 interventional studies indexed under Esophagitis.
Median enrollment 357 across the 10 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
11 studies in Esophagitis by Takeda: none open now, none under way, none of them phase 3. Of 11 finished, 4 (36%) have results posted.
Among the 11 studies in Esophagitis by Takeda, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 7 in phase 3, and was the 5th registered.
Takeda’s Esophagitis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing vonoprazan in Esophagitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 11 in Esophagitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to confirm the efficacy of TAK-438, once daily (QD), compared to lansoprazole for the maintenance treatment of healed erosive esophagitis and to determine the clinical dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: TAK-438
Drug: TAK-438
Drug: Lansoprazole
In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks. In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks. In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks. In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks.
Also known as: AG-1749
Endoscopically confirmed recurrence rate of erosive esophagitis after 24 weeks of maintenance treatment
Endoscopic recurrence of erosive esophagitis is defined as those participants who have endoscopically confirmed EE of Grade A to D as defined by the Los Angeles (LA) Classification Grading System. The definitions of each grade are: Grade O (No mucosal break), Grade A (Mucosal break \<5 mm), Grade B (Mucosal break ≥5 mm), Grade C (Mucosal break continuous between two or more folds and \<75% of the circumference) and Grade D (Mucosal break ≥75% of the circumference).
Time frame: 24 Weeks.
Endoscopically confirmed recurrence rate of erosive esophagitis after 12 weeks of maintenance treatment
Time frame: 12 Weeks.
The record gives a start of Oct 2011, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan